RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US8048863B2 · kind B2 · utility
1Cited by
2References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2007 |
| Grant date | Nov 1, 2011 |
| Priority date | — |
| Expiry date | Nov 27, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.